CMO, Ira N. Kalfus, M.D., was Chief Medical Offcer at Thar Pharmaceuticals until its acquisition by Grunenthal in 2016. Dr. Kalfus was previously Vice President of Medical Afiairs at Lev Pharmaceuticals, where he led the clinical development for Cinryze, the first HAE prophylaxis therapy, approved by the FDA in 2008. Upon the acquisition of Lev by ViroPharma Inc. in 2008, he consulted on the Cinryze commercial launch andexpansion, as well as investor relations activities for ViroPharma whichwas acquired by Shire in 2013. Dr. Kalfus is consulting Medical Director at RedHill Biopharma Ltd., directing two Phase III clinical programs. His other positions have included Aetna/US Healthcare (Medical Director), Hillside Medical Associates (Internist), and Long Island Jewish Medical Center (President of the Staff Society and Chairman of Performance Improvement). Dr. Kalfus completed residency in Internal Medicine at Long Island Jewish Medical Center and graduated from Albert Einstein College of Medicine (M.D.) and Columbia University (B.A. in Biology).